Increased Cardiovascular Risk in Patients With Human Immunodeficiency Virus Infection Under Highly Active Antiretroviral Therapy

American Journal of Cardiology

Volumn 102, Issue 3, 2008, Pages 373-374

  Zangerle, Robert ^a   Fuchs, Dietmar ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; C REACTIVE PROTEIN; GAMMA INTERFERON; IRON; LIPID; MACROPHAGE ACTIVATING FACTOR; NEOPTERIN; TRYPTOPHAN;

ATHEROGENESIS; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSTIMULATION; INFLAMMATION; LETTER; LIPID METABOLISM; PATHOGENESIS; PREDICTION; PREDICTIVE VALIDITY; PRIORITY JOURNAL;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HUMANS; MYOCARDIAL INFARCTION;

EID: 51749101262     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.04.023     Document Type: Letter

References (6)

1. Schuster I., Thöni G.J., Edérhy S., Walther G., Nottin S., Vinet A., Boccara F., Khireddine M., Girard P.M., Mauboussin J.M., et al. Subclinical cardiac abnormalities in human immunodeficiency virus-infected men receiving antiretroviral therapy. Am J Cardiol 101 (2008) 1213-1217
2. Ray K.K., Morrow D.A., Sabatine M.S., Shui A., Rifai N., Cannon C.P., and Braunwald E. Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome. Circulation 115 (2007) 3071-3078
3. Kaski JC, Consuegra-Sanchez L, Fernandez-Berges DJ, Cruz-Fernandez JM, Garcia-Moll X, Marrugat J, Mostaza J, Toro-Cebada R, González-Juanatey JR, Guzmán-Martínez G, on behalf of the SIESTA Investigators. Elevated serum neopterin levels and adverse cardiac events at 6 months follow-up in Mediterranean patients with non-ST-segment elevation acute coronary syndrome. Atherosclerosis. In press.
4. Mildvan D., Spritzler J., Grossberg S.E., Fahey J.L., Johnston D.M., Schock B.R., and Kagan J. Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection. Clin Infect Dis 40 (2005) 853-858
5. Zangerle R., Widner B., Quirchmair G., Neurauter G., Sarcletti M., and Fuchs D. Effective antiretroviral therapy reduces degradation of tryptophan in patients with HIV-1 infection. Clin Immunol 104 (2002) 242-247
6. Zangerle R., Sarcletti M., Gallati H., Reibnegger G., Wachter H., and Fuchs D. Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation. J Acquir Immune Defic Syndr 7 (1994) 1149-1156